Fati Nourhashemi

Fati Nourhashemi

Auto-generated profile, based on publicly available information

Fati Nourhashemi

Geriatrics Department, Internal Medicine and Cardiogeriatry Unit, Toulouse University Hospital, 31059 Toulouse, France

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
APAntoine Piau
Antoine Piau
RCRachel Crissey
Rachel Crissey
DBDelphine Brechemier
Delphine Brechemier
LBLaurent Balardy
Laurent Balardy
FNFati Nourhashemi
Fati Nourhashemi

1 January 2005
Verified
Journal Article
Closed access
FNF Nourhashemi
F Nourhashemi
KAK Amouyal-Barkate
K Amouyal-Barkate
SGS Gillette-Guyonnet
S Gillette-Guyonnet
CCC Cantet
C Cantet
BVB Vellas
B Vellas
RGREAL.FR Group
REAL.FR Group

25 April 2008 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
FNFati Nourhashémi
Fati Nourhashémi
POPierre Jean Ousset
Pierre Jean Ousset
SGSophie Gillette‐Guyonnet
Sophie Gillette‐Guyonnet
CCChristelle Cantet
Christelle Cantet
SASandrine Andrieu
Sandrine Andrieu
BVBruno Vellas
Bruno Vellas

25 May 2015 in JMIR Rehabilitation and Assistive Technologies
Verified
Journal Article
Open access
APAntoine Piau
Antoine Piau
YCYoann Charlon
Yoann Charlon
ECEric Campo
Eric Campo
BVBruno Vellas
Bruno Vellas
FNFati Nourhashemi
Fati Nourhashemi
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

5 July 2021 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
APAntoine Piau
Antoine Piau
ZSzara steinmeyer
zara steinmeyer
YCYoann Charlon
Yoann Charlon
LCLaetitia Courbet
Laetitia Courbet
VRVincent Rialle
Vincent Rialle
FNFati Nourhashemi
Fati Nourhashemi
Background: Recent World Health Organization reports propose wearable devices to collect information on activity and walking speed as innovative health indicators. However, mainstream consumer-grade tracking devices and smartphone apps are often inaccurate and require long-term acceptability assessment. Objective: Our aim is to assess the user acceptability of an instrumented shoe insole in frail older adults. This device monitors participants’ walking speed and differentiates active walking from shuffling after step length calibration. Methods: A multiphase evaluation has been designed: 9 older adults were evaluated in a living lab for a day, 3 older adults were evaluated at home for a month, and a prospective randomized trial included 35 older adults at home for 3 months. A qualitative research design using face-to-face and phone semistructured interviews was performed. Our hypothesis was that this shoe insole was acceptable in monitoring long-term outdoor and indoor walking. The primary outcome was participants' acceptability, measured by a qualitative questionnaire and average time of insole wearing per day. The secondary outcome described physical frailty evolution in both groups. Results: Living lab results confirmed the importance of a multiphase design study with participant involvement. Participants proposed insole modifications. Overall acceptability had mixed results: low scores for reliability (2.1 out of 6) and high scores for usability (4.3 out of 6) outcomes. The calibration phase raised no particular concern. During the field test, a majority of participants (mean age 79 years) were very (10/16) or quite satisfied (3/16) with the insole's comfort at the end of the follow-up. Participant insole acceptability evolved as follows: 63% (12/19) at 1 month, 50% (9/18) at 2 months, and 75% (12/16) at 3 months. A total of 9 participants in the intervention group discontinued the intervention because of technical issues. All participants equipped for more than a week reported wearing the insole every day at 1 month, 83% (15/18) at 2 months, and 94% (15/16) at 3 months for 5.8, 6.3, and 5.1 hours per day, respectively. Insole data confirmed that participants effectively wore the insole without significant decline during follow-up for an average of 13.5 days per 4 months and 5.6 hours per day. For secondary end points, the change in frailty parameters or quality of life did not differ for those randomly assigned to the intervention group compared to usual care. Conclusions: Our study reports acceptability data on an instrumented insole in indoor and outdoor walking with remote monitoring in frail older adults under real-life conditions. To date, there is limited data in this population set. This thin instrumentation, including a flexible battery, was a technical challenge and seems to provide an acceptable solution over time that is valued by participants. However, users still raised certain acceptability issues. Given the growing interest in wearable health care devices, these results will be useful for future developments. Trial Registration: ClinicalTrials.gov NCT02316600; https://clinicaltrials.gov/ct2/show/NCT02316600

25 April 2018 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
FNFati Nourhashemi
Fati Nourhashemi
CHClaudie Hooper
Claudie Hooper
CCChristelle E. Cantet
Christelle E. Cantet
Catherine FéartCatherine Féart
Catherine Féart
IGIsabelle Gennero
Isabelle Gennero
BVBruno Vellas
Bruno Vellas
Vitamin D deficiency is associated with an increased risk of Alzheimer’s disease and increased beta-amyloid (Aβ) in animals. Hence we sought to investigate the relationship between plasma 25-hydroxyvitamin D (25(OH)D) and cerebral Aβ in older adults with subjective memory complaints. This is a secondary analysis of the Multidomain Alzheimer Preventive Trial. Participants were 178 dementia-free individuals aged 70 years or older with data on plasma 25(OH)D and cerebral Aβ load assessed by [18F]-florbetapir positron emission tomography. Plasma 25(OH)D was measured at study baseline using a commercially available electro-chemiluminescence competitive binding assay. Standard uptake value ratios (SUVRs) were generated using the cerebellum as a reference. Brain regions assessed included the cortex, anterior cingulate, anterior putamen, caudate, hippocampus, medial orbitofrontal cortex, occipital cortex, parietal cortex, pons, posterior cingulate, posterior putamen, precuneus, semioval centre and temporal cortex. Associations were explored using fully adjusted multiple linear regression models. Participants had a mean (SD) age of 76.2 years (4.4) and 59.6% were female. The mean (SD) plasma 25(OH)D level was 22.4 ng/ml (10.8) and the mean (SD) cortical SUVR was 1.2 (0.2). We did not find any cross-sectional associations (p > 0.05) between baseline 25(OH)D levels and Aβ in any of the brain regions studied. These preliminary results suggest that circulating 25(OH)D is not associated with cerebral Aβ in older adults. Further longitudinal studies with the measurement of mid-life vitamin D status are required to explore the relationship between vitamin D and Aβ accrual over time, thereby circumventing the shortfalls of a cross-sectional study.